Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.

Biotechnology

Health Care

Synklino

Synklino's headquarters in Lyngby, Denmark

The Leadership Team at Synklino oversees the strategic direction and operational management of the company, ensuring the successful development and commercialization of their CMV-specific immunotoxin. This team collaborates closely to make high-level decisions, secure funding, manage resources, and guide clinical and regulatory strategies to eradicate cytomegalovirus infection.

Leadership Team

The Board of Directors at Synklino provides strategic guidance, oversight, and governance to ensure that the company remains focused on its mission to develop a CMV-specific immunotoxin. They supervise executive management, make high-level policy decisions, and ensure financial and regulatory compliance to drive the company toward sustainable growth and success.

Board of Directors

The Scientific Team at Synklino focuses on the research and development of CMV-specific immunotoxins. This team conducts experiments, manages laboratory operations, and drives the discovery and pharmacological evaluation of targeted therapies to eradicate cytomegalovirus infections.

Scientific Team

The Advisory Team at Synklino provides expert guidance on scientific and strategic matters related to the development of the company's CMV-specific immunotoxin. Comprising scientific advisors and a senior strategic advisor, the team ensures that the company's efforts align with the latest scientific research and strategic business objectives.

��

People (5)

Jobs (0)

Other teams

Board of Directors

Scientific Team

Advisory Team

��������

People (5)

Jobs (0)

Other teams

Board of Directors

Scientific Team

Advisory Team

��